Glenmark gets FDA nod for generic Ranexa
Glenmark has received the Food and Drug Administration’s blessing for its generic of Gilead’s Ranexa (ranolazine extended-release tablets). The product will be avaialable in dosage strengths of 500 mg and 1,000 mg.
The product is used to treat adults with chronic angina. Ranexa may be used with other medicines that are used for heart problems and blood pressure control.
Ranexa extended-release tablets, 500 mg and 1,000 mg had a market value of approximately $929 million for the 12 months ended May 2019, according to IQVIA.
No comments found